A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

Part of paid clinical trials in Hackensack, New Jersey.

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT07543055
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BPX-601 — GENETIC
    Administered per protocol

Study Details

This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies. The study is looking at: * What side effects BPX-601 might cause * What is the best dose of BPX-601 * How well BPX-601 may work to destroy prostate cancer

Key Dates

Start date
Jul 7, 2026
Status verified
Jun 2026
Primary completion
Feb 5, 2030
Completion
Apr 25, 2031

Study Design

Enrollment
36 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BPX-601 monotherapy

Primary Outcome Measure

Occurrence of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 4 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
John Theurer Cancer CenterHackensackNew Jersey07601-

Find similar trials in Hackensack, NJ

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
John Theurer Cancer Center· Hackensack, NJ

Related Studies